Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models
Sarah Raevens, Michael B. Fallon – 5 May 2018 – Hepatopulmonary syndrome (HPS) is a relatively common and potentially severe pulmonary complication of cirrhosis with increased risk of mortality. In experimental models, a complex interaction between pulmonary endothelial cells, monocytes, and the respiratory epithelium, which produces chemokines, cytokines, and angiogenic growth factors, causes alterations in the alveolar microvasculature, resulting in impaired oxygenation.